收藏切换
Analysis of the Application of Model-informed Drug Development in Pediatric Drug Development Taking Rivaroxaban Granules for Oral Suspension as an Example
收藏切换
Pengyu PAN1, Hongcan HAN1, Jinjing CHE2, Jun WANG1, *
Chinese Journal of Pharmaceuticals | 2022, 53(11) : 1622 - 1627
Less
收藏切换
Chinese Journal of Pharmaceuticals | 2022, 53(11): 1622-1627
Analysis of the Application of Model-informed Drug Development in Pediatric Drug Development Taking Rivaroxaban Granules for Oral Suspension as an Example
Full
Pengyu PAN1, Hongcan HAN1, Jinjing CHE2, Jun WANG1, *
Affiliations
  • 1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022
  • 2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850
Published: 2022-11-10 doi: 10.16522/j.cnki.cjph.2022.11.016
Outline
收藏切换

Rivaroxaban granules for oral suspension was approved by FDA in 2021 for the treatment of venous thromboembolism(VTE) and prevention of VTE recurrence in patients under age of 18 years after at least 5 days of initial parenteral anticoagulation treatment. The development of rivaroxaban granules for oral suspension for pediatric indications was based on adult data. Model-informed drug development method was adopted to support the initial dosage selection in pediatric clinical trials, dose adjustment of phase Ⅱ and Ⅲ clinical trials. This paper analyzes the relative pediatric studies and FDA’s evaluation considerations of rivaroxaban granules for oral suspension, and discusses the application of model-informed drug development in pediatric drug development.

rivaroxaban granules for oral suspension  /  pediatric drug  /  dose selection  /  model-informed drug development
潘鹏玉, 韩鸿璨, 车津晶, 王骏. 以利伐沙班干混悬剂为例分析模型引导的药物研发在儿科药物开发中的应用. 中国医药工业杂志, 2022 , 53 (11) : 1622 -1627 . DOI: 10.16522/j.cnki.cjph.2022.11.016
Pengyu PAN, Hongcan HAN, Jinjing CHE, Jun WANG. Analysis of the Application of Model-informed Drug Development in Pediatric Drug Development Taking Rivaroxaban Granules for Oral Suspension as an Example[J]. Chinese Journal of Pharmaceuticals, 2022 , 53 (11) : 1622 -1627 . DOI: 10.16522/j.cnki.cjph.2022.11.016
Year 2022 volume 53 Issue 11
67
10
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2022.11.016
  • Receive Date:2022-08-29
  • Online Date:2026-11-12
  • Published:2022-11-10
Article Data
Affiliations
History
  • Received:2022-08-29
Affiliations
    1.Center of Drug Evaluation, National Medical Products Administration, Beijing 100022
    2.Beijing Institute of Pharmacology and Toxicology, Beijing 100850
References
Share
https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.11.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT